ATE402956T1 - Neue, mhc klasse ii assoziierte peptide - Google Patents

Neue, mhc klasse ii assoziierte peptide

Info

Publication number
ATE402956T1
ATE402956T1 AT03748078T AT03748078T ATE402956T1 AT E402956 T1 ATE402956 T1 AT E402956T1 AT 03748078 T AT03748078 T AT 03748078T AT 03748078 T AT03748078 T AT 03748078T AT E402956 T1 ATE402956 T1 AT E402956T1
Authority
AT
Austria
Prior art keywords
mhc class
antigenic peptides
associated peptides
tumors
present
Prior art date
Application number
AT03748078T
Other languages
English (en)
Inventor
Harald Kropshofer
Till Roehn
Anne Vogt
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Application granted granted Critical
Publication of ATE402956T1 publication Critical patent/ATE402956T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4748—Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70539—MHC-molecules, e.g. HLA-molecules

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cell Biology (AREA)
  • Dermatology (AREA)
  • Pulmonology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
AT03748078T 2002-10-02 2003-09-24 Neue, mhc klasse ii assoziierte peptide ATE402956T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP02022224 2002-10-02

Publications (1)

Publication Number Publication Date
ATE402956T1 true ATE402956T1 (de) 2008-08-15

Family

ID=32049974

Family Applications (1)

Application Number Title Priority Date Filing Date
AT03748078T ATE402956T1 (de) 2002-10-02 2003-09-24 Neue, mhc klasse ii assoziierte peptide

Country Status (9)

Country Link
US (2) US20050202009A1 (de)
EP (1) EP1549673B1 (de)
JP (1) JP2006518982A (de)
CN (3) CN101260154A (de)
AT (1) ATE402956T1 (de)
AU (1) AU2003267401A1 (de)
CA (1) CA2498854A1 (de)
DE (1) DE60322559D1 (de)
WO (1) WO2004031230A2 (de)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007097828A2 (en) * 2006-01-06 2007-08-30 The Johns Hopkins University Method for identifying and validating dominant t helper cell epitopes using an hla-dm-assisted class ii binding assay
US8569244B2 (en) * 2007-08-20 2013-10-29 Oncotherapy Science, Inc. FOXM1 peptide and medicinal agent comprising the same
JP5147852B2 (ja) 2007-10-18 2013-02-20 株式会社メディカル・プロテオスコープ 手術後の予後を推定する方法及び診断キット
US9279011B2 (en) * 2009-05-05 2016-03-08 The Johns Hopkins University Phosphopeptides as melanoma vaccines
JP5872468B2 (ja) * 2009-07-24 2016-03-01 ロード アイランド ホスピタル アスパラギニル−β−ヒドロキシラーゼ発現腫瘍に対する樹状細胞ワクチン
GB201214007D0 (en) * 2012-08-07 2012-09-19 Scancell Ltd Anti-tumour immune responses to modified self-epitopes
EP3791891A1 (de) * 2014-07-17 2021-03-17 Brian J. Czerniecki Identifikation von immunogenen mhc-klasse-ii-peptiden für immunbasierte therapie
WO2016128060A1 (en) * 2015-02-12 2016-08-18 Biontech Ag Predicting t cell epitopes useful for vaccination
GB201507030D0 (en) * 2015-04-24 2015-06-10 Immatics Biotechnologies Gmbh Immunotherapy against lung cancers, in particular NSCLC
WO2017100789A1 (en) * 2015-12-11 2017-06-15 Expression Pathology, Inc. Srm/mrm assays
US20190070275A1 (en) * 2016-02-22 2019-03-07 Oceanside Biotechnology Neoantigen compositions and methods of using the same in immunooncotherapy
US11427614B2 (en) 2017-04-10 2022-08-30 Immatics Biotechnologies Gmbh Peptides and combination thereof for use in the immunotherapy against cancers
MX2019012225A (es) 2017-04-10 2019-12-09 Immatics Biotechnologies Gmbh Peptidos y combinaciones de los mismos para el uso en la inmunoterapia contra diversos tipos de cancer.
EP3810754A1 (de) * 2018-06-19 2021-04-28 Fondazione Telethon Herstellung von manipulierten dendritischen zellen und verwendungen davon
JP7359864B2 (ja) 2019-07-10 2023-10-11 中外製薬株式会社 クローディン６結合分子およびその使用
CN112618712A (zh) * 2021-01-21 2021-04-09 武汉轻工大学 一种含波形蛋白的佐剂及应用

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4376110A (en) * 1980-08-04 1983-03-08 Hybritech, Incorporated Immunometric assays using monoclonal antibodies

Also Published As

Publication number Publication date
DE60322559D1 (de) 2008-09-11
CA2498854A1 (en) 2004-04-15
EP1549673A2 (de) 2005-07-06
EP1549673B1 (de) 2008-07-30
CN101185754A (zh) 2008-05-28
WO2004031230A3 (en) 2005-01-13
US20050202009A1 (en) 2005-09-15
CN1688602A (zh) 2005-10-26
CN100347191C (zh) 2007-11-07
CN101260154A (zh) 2008-09-10
AU2003267401A1 (en) 2004-04-23
JP2006518982A (ja) 2006-08-24
US20070073042A1 (en) 2007-03-29
WO2004031230A2 (en) 2004-04-15

Similar Documents

Publication Publication Date Title
DE60322559D1 (de) Neue, mhc klasse ii assoziierte peptide
HUP0500345A2 (hu) Készítmények és alkalmazások tüdőrák kezelésére és diagnosztizálására
CY1117387T1 (el) ΜΟΝΟΚΛΩΝΙΚΑ ΑΝΤΙΣΩΜΑΤΑ Ν-11 ΔΙΑΣΠΑΣΜΕΝΟΥ β-ΑΜΥΛΟΕΙΔΟΥΣ, ΣΥΝΘΕΣΕΙΣ, ΜΕΘΟΔΟΙ ΚΑΙ ΧΡΗΣΕΙΣ
ATE410446T1 (de) Zusammensetzungen zur behandlung und diagnose von eierstockkrebs
CY1107042T1 (el) Ανασυνδυασμενη πρωτεϊνη που φερει επιτοπους του ανθρωπινου ιου των θηλωματων που εχουν εισαχθει σε μια πρωτεϊνη αδενυλικης κυκλασης ή τμηματα αυτης, θεραπευτικες χρησεις αυτων
MXPA05008128A (es) Peptidos derivados de survivina y uso de los mismos.
NZ516381A (en) Lung tumor proteins in the therapy and diagnosis of lung cancer
NZ512247A (en) Compositions and methods for therapy and diagnosis of ovarian cancer
MX344216B (es) Productos geneticos expresados de forma diferencial en tumores y su uso.
CY1107973T1 (el) Σχετιζομενα με ογκους πεπτιδια, που συνδεονται ετεροκλητως με μορια κλασεως ιι αντιγονου ανθρωπινων λευκοκυτταρων
HK1093314A1 (en) Recombinant adenylate cyclase toxin of bordetella induces t cell responses against tumoral antigens
DE69931482D1 (de) Isolierte peptide die aminosäuresequenzen von ny-eso-1 entsprechen und an mhc-klasse i und mhc klasse ii moleküle binden, und deren verwendungen
HUP0302566A2 (hu) Készítmények és eljárások emlőrák gyógykezelésére és diagnosztizálására
ATE239035T1 (de) Durch hla-b44 moleküle präsentierte tumor- abstossungsantigene und ihre verwendungen
ATE475710T1 (de) Zusammensetzungen und verfahren für die therapie und diagnose von ovariumkrebs
ATE308565T1 (de) Immunogene alk (anaplastic lymphoma kinase) peptide
DE60120507D1 (de) Menschliches leucinereiche wiederholungen enthaltendes protein, vorwiegend im dünndarm exprimiert, hlrrsi1
DE69531167D1 (de) Verfahren zum nachweis und therapie von schuppenartigen zellkarzinomen und blasen-karzinomen insbesondere zur bestimmung der anwesenheit und behandlung von minimalen resterkrankungen, micrometastasierung oder der verbreitung von solchen karzinomtypen
EA202192991A1 (ru) Новые раковые антигены и сопутствующие способы
ATE480250T1 (de) Neue trp2-isoform mit cytotoxischen t-lymphozyten-epitopen mit hla-a2-restriktion
CY1108790T1 (el) Συνθεσεις για τη θεραπεια και διαγνωση ωοθηκικου καρκινου

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties